Akari Therapeutics

View the org chart displaying its 12 main executives

Most searched biographies at Akari Therapeutics

• Rachelle Jacques, President and Chief Executive Officer
• Samir Patel, Director
• Ray Prudo, Executive Chairman of the Board

Popular executive movements at Akari Therapeutics

• Samir Patel has joined the company as Director  (posted on December 4 2023).
• Beth-Anne Lang has joined the company as Senior Vice President, Regulatory Affairs  (posted on August 3 2023).
• Wendy Dicicco has joined the company as Interim Chief Financial Officer  (posted on July 20 2023).

Create your alert
to follow the executive moves at Akari Therapeutics.

Akari Therapeutics has 2,275 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Bruker has announced the acquisition of NanoString Technologies  (posted on April 18 2024).
• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (posted on April 16 2024).
• Nurix Therapeutics has just announced a $175 Million fundraising (posted on April 13 2024).

Popular contacts in Biotechnology

• Vik Bajaj - Director at Interline Therapeutics
• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Akari Therapeutics

• Akari Therapeutics Narrows Pipeline Focus | Akari Therapeutics
• Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy | Akari Therapeutics
• Press Releases | Akari Therapeutics
• Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress | Akari Therapeutics
• Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) | Akari Therapeuti
• Press Releases | Akari Therapeutics
• Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies | Akari Therapeutics
• Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting | Akari Therapeutics
• Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress | Akari Therapeutics
• Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting | Akari Therapeutics
• View more press releases Close

Social media about Akari Therapeutics

• Akari Therapeutics on Wikipedia, Google News & Yahoo Finance
• Akari Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Ray Prudo

Call Akari Therapeutics at +1 646...

View the org chart

Register to receive your alert

Report an error